Podcasts about 1L

From the first day of 1L year, the pressure to compete with your peers can feel overwhelming. But what if the secret to a fulfilling legal career isn't a higher grade, but a deeper connection?In this episode of the ABA Law Student Podcast, host Eve Albert sits down with Spencer Pahlke, a trial attorney at WalkUp, Melodia, Kelly, and Schoenberger and a lecturer at Berkeley Law. Spencer breaks down the realities of a plaintiff's side practice—from representing those who have suffered catastrophic injuries to the chaotic, exciting "mishmash" of a typical workday.We dive deep into the power of the plaintiff's bar, the importance of pay transparency in the legal field, and how the National Plaintiff's Law Association (NPLA) is helping students get their foot in the door. Plus, learn about fortheplaintiff.org, a platform offering students paid opportunities to work on real-world projects. Whether you're a 3L weighing your career options or a 1L looking for community, this conversation offers a roadmap for finding passion and purpose beyond the classroom.(00:00) - Intro: Shifting from Competition to Community (01:22) - Meet Spencer Pahlke: Trial Attorney and Berkeley Law Lecturer (03:32) - Defining Plaintiff's Side Practice and Catastrophic Injury Law (05:30) - The Human Element: Advocating for the Wronged (07:30) - A Day in the Life: From Jury Consultants to Engineering Classes (09:40) - Business of Law: Small Firms and Business Development (11:38) - The Power of Plaintiff Bar Associations (13:32) - Inside the National Plaintiff's Law Association (NPLA) (14:50) - Paid Opportunities for Students via fortheplaintiff.org (17:44) - The Fight for Pay Transparency in the Legal Field (20:44) - Balancing Practice with Passion Projects and Teaching (24:54) - Advice for Students: Viewing Classmates as Partners, Not Rivals (27:31) - Host Debrief: Career Stability vs. Personal Fulfillment (31:10) - The Value of 1L Summer Internships (Even the "Bad" Ones) (32:53) - Finding Your "Why": Persevering Through Law School (35:58) - Closing: ABA Membership and Next Steps Click here to view the episode transcript.

Mishna Yomi - Me'ilah 2:9-3:1L'uli Nishmas Etta Ahuva bas YaakovMar 14, 2026Shab25 Adar 5786

Mishna Yomi - Kerisus 5:8-6:1L'uli Nishmas Etta Ahuva bas YaakovMar 3, 2026Tue14 Adar 5786

Hear from John Hynes, Quinn Hughes, Filip Gustavsson and MORE following a 3-1L to St. Louis as heard @KFAN1003

Mishna Yomi - Kerisus 4:3-5:1L'uli Nishmas Etta Ahuva bas YaakovFeb 27, 2026Fri10 Adar 5786

Two candidates vying for the GOP nomination in the 1L-13 congressional race discuss many issues surrounding domestic policy including the economy, healthcare, ICE agents, and a potential national ban on abortion at the IL-13 Republican Candidate Forum sponsored by Illinois Public Media, the Champaign County NAACP, and the League of Women Voters.

Aujourd'hui je voulais vous partager quelques reflexions à coeur ouvert sur ce qu'il se passe actuellement en France... Promis c'est pas l'épisode de la dépression, c'est justement pour qu'on sache qu'on est pas solo, qu'on est ensemble

Mishna Yomi - Temurah 6:5-7:1L'uli Nishmas Etta Ahuva bas YaakovFeb 11, 2026Wed24 Shevat 5786

Mishna Yomi - Temurah 7:6 -Kerisus 1:1L'uli Nishmas Etta Ahuva bas YaakovFeb 14, 2026Shabbos27 Shevat 5786

Behind every confident lawyer is someone who helped them find their footing. In the latest episode of Real Cases, we explore the mentorships—with deans, with professors, and with working attorneys—that help Stetson students navigate law school and launch meaningful careers. Professors Catherine Cameron and Assistant Deans Catherine B. Martin, Latoya Edwards, and Steve A. Maxwell join us to discuss what mentoring looks like at every stage of law school, from your transition into 1L year through bar prep and career planning. The conversation highlights Stetson's unique Inns program, our support for first-generation and non-traditional students, and how early guidance helps students gain real-world perspective before entering the profession.

Mishna Yomi - Temurah 2:3-3:1L'uli Nishmas Etta Ahuva bas YaakovFeb 1, 2026Sun14 Shevat 5786

Conner is a Touro University Jacob D. Fuchsberg Law Center graduate and currently works as a Litigation and Enforcement Associate at Ropes & Gray. Conner's journey to Law School and the Law is a story of a desire to help others, make a bit more money, and get the experience to work in the greatest city in the world. In this episode, Conner and I discussed his reasons to go to Law School, growing up on Long Island (fellow Long Islanders), his unique experience as part of the part-time evening program, and his 1L experience. As well, Conner spoke about his day-to-day life as a Litigation associate in BigLaw, dispelling some BigLaw myths, and his exceptional experience thus far. All in all, Conner preaches the importance of having a schedule, staying organized, and executing at every step of the way! Conner's LinkedIn: https://www.linkedin.com/in/conner-purcell-790193150Be sure to check out the Official Sponsors for the Lawyers in the Making Podcast:Rhetoric - Empowers your teaching and training with AI that strengthens learning, protects integrity, and proves authentic understanding, for students and professionals alike, with CICERO. Find them here: userhetoric.comThe Law School Operating System™ Recorded Course - This course is for ambitious law students who want a proven, simple system to learn every topic in their classes to excel in class and on exams. Go to www.lisablasser.com, check out the student tab with course offerings, and use code LSOSNATE10 at checkout for 10% off Lisa's recorded course!Start LSAT - Founded by former guest and 22-year-old superstar, Alden Spratt, Start LSAT was built upon breaking down barriers, allowing anyone access to high-quality LSAT Prep. For $110, you get the Start LSAT self-paced course, and using code LITM10, you get 10% off the self-paced course! Check out Alden and Start LSAT at startlsat.com and use code LITM10 for 10% off the self-paced course!Lawyers in the Making Podcast is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Get full access to Lawyers in the Making Podcast at lawyersinthemaking.substack.com/subscribe

A struggling 1L writes in seeking advice. Ben and Nate encourage him to be honest with himself about what he wants out of law school.Read more on our website. Email daily@lsatdemon.com with questions or comments. Watch this episode on YouTube!

Mishna Yomi - Erchin 7:5-8:1L'uli Nishmas Etta Ahuva bas YaakovJan 20, 2026Tue2 Shevat 5786

Mishna Yomi - Erchin 3:5-4:1L'uli Nishmas Etta Ahuva bas YaakovJan 10, 2026Shab21 Teves 5786

Mishna Yomi - Erchin 4:4-5:1L'uli Nishmas Etta Ahuva bas YaakovJan 12, 2026Mon23 Teves 5786

Mishna Yomi - Erchin 5:6-6:1L'uli Nishmas Etta Ahuva bas YaakovJan 15, 2026Thu26 Teves 5786

Bien le bonjouuuuuur d'une petite dame qui revient après 2 mois d'absence et j'en suis DÉSOLÉE ❤️Pour fêter la fin de l'année, je voulais partager avec vous 7 choses que je vais laisser en 2025... Et que je suis très très heureuse de laisser derrière moi parce que c'était encombrant !J'espère que l'épisode vous plaira et venez me dire sur Insta ce que VOUS vous laissez en 2025, je suis curieuse de savoir ✨RessourcesMon post sur "arrêter de penser comme une pauvre":https://www.instagram.com/p/DQ9us2tkeOF/?img_index=1L'épisode sur l'anxiété sociale :https://smartlink.ausha.co/green-et-soi-meme/19-anxiete-sociale-j-arrete-d-etre-dans-le-deniMa merveilleuse thérapeute que je vous recommande : https://www.instagram.com/manonboissiere_/Vous avez -10% sur TOUTES vos consultations avec mon code GSM10Adresse à laquelle envoyer vos courriers du coeur :podcast.greenetsoimeme@outlook.comJe vous attend sur Instagram @greenetsoimeme !Sinon, vous pouvez aussi laisser un avis sur votre plateforme d'écoute et vous abonnez pour ne louper aucun épisode de Green et Soi-même

Mishna Yomi - Bechoros 6:12-7:1L'uli Nishmas Etta Ahuva bas YaakovDec 21, 2025Sun1 Teves 5786

Mats Zuccarello and John Hynes join the postgame show @KFAN1003 following a 5-1L to Colorado

Mishna Yomi - Bechoros 5:6-6:1L'uli Nishmas Etta Ahuva bas YaakovDec 15, 2025Mon25 Kislev 5786

Mishna Yomi - Bechoros 4:10-5:1L'uli Nishmas Etta Ahuva bas YaakovDec 12, 2025Fri22 Kislev 5786

Mishna Yomi - Bechoros 2:9-3:1L'uli Nishmas Etta Ahuva bas YaakovDec 5, 2025Fri15 Kislev 5786

Mishna Yomi - Bechoros 3:4-4:1L'uli Nishmas Etta Ahuva bas YaakovDec 7, 2025Sun17 Kislev 5786

Featuring an interview with Dr Priyanka Sharma, including the following topics: Endocrine therapy for hormone receptor-positive, HER2-negative high-risk localized breast cancer (0:00) Johnston SR et al. monarchE: Primary overall survival (OS) results of adjuvant abemaciclib + endocrine therapy (ET) for HR+, HER2-, high-risk early breast cancer (EBC). ESMO 2025;Abstract LBA13. Durvalumab in combination with neoadjuvant chemotherapy for localized triple-negative breast cancer (TNBC) (3:25) Loibl S et al. Durvalumab in combination with neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC) – Long-term analysis from the GeparNuevo trial. ESMO 2025;Abstract 292MO.  Efficacy and safety findings with TROP2-directed antibody-drug conjugates for metastatic TNBC (5:11) Cortés JC et al. Primary results from ASCENT-03: A randomized phase III study of sacituzumab govitecan (SG) vs chemotherapy (chemo) in patients (pts) with previously untreated advanced triple-negative breast cancer (TNBC) who are unable to receive PD-(L)1 inhibitors (PD-[L]1i). ESMO 2025;Abstract LBA20.  de Azambuja E et al. Patient-reported outcomes (PROs) with sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in patients (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC) in the phase III ASCENT-04/KEYNOTE-D19 study. ESMO 2025;Abstract LBA22.  Dent R et al. First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial. ESMO 2025;Abstract LBA21.  CME information and select publications

John Hynes, Mats Zuccarello and more join the postgame show following a 4-1L in Calgary as heard @KFAN1003 

In this episode, Byron D. Brooks (MoSoul), 1L in Section 3 at Howard University School of Law, and Pauline Wanjiru Irungu, LL.M. candidate at American University Washington College of Law, sit down with Adrienne Packard, Director of Student Affairs at Howard Law. Together, they explore the real mental health landscape of legal education, define the meaning of Healing Justice, and offer tools for survival, sustainability, and collective well-being within our legal communities.Please note, the positions and opinions expressed by the speakers are strictly their own, and do not necessarily represent the views of their employers, nor those of the D.C. Bar, its Board of Governors or co-sponsoring Communities and organizations.Want to get ahead of the pack? Joining the D.C. Bar Law Student Community (LSC) can get you there. Your LSC membership will provide resume and skills boosting opportunities and one-on-one access to local practicing attorneys. To learn more, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠click here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.

Featuring an interview with Dr Priyanka Sharma, including the following topics: Patient-reported outcomes from the SERENA-6 trial of camizestrant with a CDK4/6 inhibitor for patients with HR-positive, HER2-negative advanced breast cancer and ESR1 mutations emerging during first-line endocrine-based therapy (0:00) Mayer E et al. Patient-reported outcomes (PROs) from the SERENA-6 trial of camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i) for emergent ESR1m during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC). ESMO 2025;Abstract 486MO. Imlunestrant and abemaciclib versus fulvestrant and abemaciclib for ER-positive, HER2-negative advanced breast cancer: An indirect treatment comparison of 3 Phase III trials (3:00) Bidard FC et al. Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): An indirect treatment comparison (ITC) of three phase 3 trials. ESMO 2025;Abstract 496P . Giredestrant in the treatment of ER-positive, HER2-negative breast cancer: The Phase III evERA Breast Cancer and EMPRESS trials (5:39) Mayer E et al. Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i): Primary results of the phase III evERA BC trial. ESMO 2025;Abstract LBA16. Llombart-Cussac A et al. Preoperative window-of-opportunity study with giredestrant or tamoxifen (tam) in premenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) and Ki67≥10% early breast cancer (EBC): The EMPRESS study. ESMO 2025;Abstract 294MO. Capivasertib/fulvestrant as first- and second-line endocrine-based therapy for PIK3CA/AKT1/PTEN-altered HR-positive advanced breast cancer in the CAPItello-291 trial and gedatolisib/fulvestrant with or without palbociclib for HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer in the VIKTORIA-1 trial.(10:25) Rugo HS et al. Capivasertib plus fulvestrant as first and second-line endocrine-based therapy in PIK3CA/AKT1/PTEN-altered hormone receptor-positive advanced breast cancer: Subgroup analysis from the phase 3 CAPItello-291 trial. ESMO 2025;Abstract 526P. Hurvitz SA et al. Gedatolisib (geda) + fulvestrant ± palbociclib (palbo) vs fulvestrant in patients (pts) with HR+/ HER2-/PIK3CA wild-type (WT) advanced breast cancer (ABC): First results from VIKTORIA-1. ESMO 2025;Abstract LBA17. CME information and select publications

Mishna Yomi - Chulin 12:5 -Bechoros 1:1L'uli Nishmas Etta Ahuva bas YaakovThu7 Kislev 5786

Nima is a Northwestern University Pritzker School of Law graduate and currently works as the Founder and CEO of JusticeArch. Nima's journey demonstrates that betting on yourself and succeeding in that bet can yield the greatest dividends throughout life. Nima and I started prior to Law School, where at UCLA, he would cold call his way into his first job, and explore his interests in policy and non-profit organizations. Law School was always on his mind, and during the intermission between college and law school, Nimma recommended the various pre-law school legal experiences he had and just how impactful they were. Then we moved to Nima's introduction to Northwestern University Pritzker School of Law, on a full scholarship. Going into his first year, Nima would face some health problems, making an already tough 1L year into a nightmare. But, despite it all, Nima persevered, a huge topic of importance for him. We then spoke about Nimma's various legal internships during Law School and his decision to open up JusticeArch in his 2L year. What makes the JusticeArch story so fascinating is that it was a completely different service at the beginning than it is today. After realizing what he sought in JusticeArch may not work, Nima would pivot into what it is today, a Legal Marketing infrastructure built by JDs, for JDs. Finally, Nima and I spoke about the biggest decision of all and why he did it, turning down an offer from Kirkland & Ellis, and going all in on himself and Justice Arch. Nima shows in this episode that the greatest bet one could make is the bet on themselves!Nimma's LinkedIn: https://www.linkedin.com/in/nima-ostowariJusticeArch: https://justicearch.comBe sure to check out the Official Sponsors for the Lawyers in the Making Podcast:Rhetoric - takes user briefs and motions and compares them against the text of opinions written by judges to identify ways to tailor their arguments to better persuade the judges handling their cases. Rhetoric's focus is on persuasion and helps users find new ways to improve their odds of success through more persuasive arguments. Find them here: userhetoric.comThe Law School Operating System™ Recorded Course - This course is for ambitious law students who want a proven, simple system to learn every topic in their classes to excel in class and on exams. Go to www.lisablasser.com, check out the student tab with course offerings, and use code LSOSNATE10 at checkout for 10% off Lisa's recorded course!Start LSAT - Founded by former guest and 22-year-old superstar, Alden Spratt, Start LSAT was built upon breaking down barriers, allowing anyone access to high-quality LSAT Prep. For $110, you get yourself the Start LSAT self-paced course, and using code LITM10 you get 10% off the self-paced course! Check out Alden and Start LSAT at startlsat.com and use code LITM10 for 10% off the self-paced course!Lawyers in the Making Podcast is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Get full access to Lawyers in the Making Podcast at lawyersinthemaking.substack.com/subscribe

When LSAC accused a student of cheating, claiming his score jump had “Powerball odds,” Ben and Nathan dig into the details. They break down LSAC's vague statistical claims and explain why big score increases are both possible and common for serious students. They also urge the student to document their prep to show clear evidence of progress.Also in this episode:Early 1L and 2L law firm hiring trendsA student asks whether to keep taking undergrad classes to boost their GPAShould you ask law schools for an application fee waiver?Links Mentioned:https://lsat.link/grades ⁠Study with our Free Plan⁠⁠Download our iOS app⁠Watch Episode 532 on YouTubeCheck out all of our “What's the Deal With” segmentsGet caught up with our ⁠Word of the Week⁠⁠ library0:00 - Is It Ever Worth Paying for Law School? 23:40 - LSAC Accuses a Student of Cheating 49:20 - 1L and 2L Law Firm Hiring Trends 56:37 - Should I Keep Taking Classes? 1:03:37 - Community Colleges Offering A+ Grades 1:09:59 - Pearls vs. Turds 1:15:06 - Should You Ask for a Fee Waiver? 1:19:44 - Word of the Week — Demarcating

Mishna Yomi - Chulin 5:5-6:1L'uli Nishmas Etta Ahuva bas YaakovNov 8, 2025Shab17 Cheshvan 5786

Featuring an interview with Dr Aaron Lisberg, including the following topics: Prevention and Management of Adverse Events of Special Interest with Datopotamab Deruxtecan (Dato-DXd) (0:00) Rugo H et al. US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan. Support Care Cancer 2025;33(9):756. Abstract Lisberg A et al. Datopotamab deruxtecan-associated select adverse events: Clinical practices and institutional protocols on prophylaxis, monitoring, and management. Oncologist 2025;[Online ahead of print]. Abstract Meric-Bernstam F et al. Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis. Oncologist 2025;30(3). Abstract Novel Strategies Combining Dato-DXd with Osimertinib (10:44) Lu S et al. TROPION-Lung14: A phase 3 study of osimertinib ± datopotamab deruxtecan (Dato-DXd) as first-line (1L) treatment for patients with EGFR-mutated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC). ASCO 2025;Abstract TPS8647. Nadal E et al. TROPION-Lung15: A phase III study of datopotamab deruxtecan (Dato-DXd) ± osimertinib vs platinum doublet chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) and disease progression on prior osimertinib. ELCC 2025;Abstract 124TiP. Intracranial Activity Observed with TROP2-Targeting Antibody-Drug Conjugates (15:14) Felip E et al. Brain metastases and actionable genetic alterations with sacituzumab govitecan versus docetaxel in metastatic non-small cell lung cancer: Subgroups of the phase III EVOKE-01 trial. ELCC 2025;Abstract 13P. Lisberg A et al. Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05. ASCO 2024;Abstract 8593. Pons-Tostivint E et al. Intracranial efficacy of datopotamab deruxtecan (Dato- DXd) in patients with advanced/metastatic NSCLC in TROPION-Lung01. WCLC 2025;Abstract OA10.01. CME information and select publications

Send us a textThe NoJetStress Podcast is a traveler wellbeing podcast for frequent business travelers covering health and peak performance on the road as well as to help business travelers maintain optimal health and avoid burnout no matter how much they travel.  Christopher Babayode, a Corporate Travel Wellness Expert shares his insights on Traveler Wellness.The Aircraft: Place of Least Leverage (POLL)Mindset Shift: Once you're airborne, control is out of your hands—accept and adapt.The Cabin as a Desert: Dry air, lower pressure, radiation, and zero control make the cabin a challenging environment.Hostile Elements at AltitudeLow Humidity → Rapid dehydration riskLow Pressure → Less oxygen, more fatigueRadiation Exposure → Increased risk at cruise altitudeLack of Control → Unpredictable schedules, cabin noise, and food qualityIn-Flight Defensive StrategyFocus: What you CAN control—your micro-environment.“Defend, hydrate, insulate” is the policy.Actionable TakeawaysHydrate Relentlessly: Bring a 1L water bottle, fill it after security, and aim for 1L per 4 hours in the air. Judge hydration by urine color.Protect Your Senses: Use noise-canceling headphones to reduce engine hum; eye mask to block light and preserve melatonin (and quality rest).Ditch Diuretics: Avoid coffee, sodas, and alcohol—choose water at every opportunity.You can subscribe to this podcast by searching 'BusinessTravel360' on your favorite podcast player or visiting BusinessTravel360.comThis podcast was created by Christopher Babayode and distributed by BusinessTravel360.  For more information about NoJetStress, visit us at NoJetStress.comSupport the show

Mishna Yomi - Chulin 3:7-4:1L'uli Nishmas Etta Ahuva bas YaakovNov 2, 2025Sun11 Cheshvan 5786

Filip Gustavsson and John Hynes join the postgame show @KFAN1003 following a 4-1L to the Pens.  Find all your @mnwild audio needs at www.wild.com/PONDcast and at www.x.com/PONDcast 

Mishna Yomi - Menachos 13:11 -Chulin 1:1L'uli Nishmas Etta Ahuva bas YaakovOct 21, 2025Tue29 Tishrei 5786

Featuring an interview with Dr Aaron Lisberg, including the following topics: Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) for Patients with Previously Treated EGFR-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC): A Pooled Analysis of the TROPION-Lung01 and TROPION-Lung05 Trials (0:00) Ahn M-J et al. Efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously-treated EGFR-mutated advanced non-small cell lung cancer (NSCLC): A pooled analysis of TROPION-Lung01 and TROPION-Lung05. ESMO Asia 2024;Abstract LBA7 Ahn M-J et al. A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC. J Thorac Oncol 2025;[Online ahead of print]. Abstract Sacituzumab Tirumotecan for Previously Treated Advanced EGFR-Mutated NSCLC: Results from the Randomized OptiTROP-Lung03 Study (7:08) Fang W et al. Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: Multicentre, open label, randomised controlled trial. BMJ 2025;389:e085680. Abstract Zhang L et al. Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study. ASCO 2025;Abstract 8507. Combination of Dato-DXd and Immunotherapy as First-Line Therapy for Patients with Advanced NSCLC (13:12) Cuppens K et al. First-line (1L) datopotamab deruxtecan (Dato-DXd) + durvalumab ± carboplatin in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohorts 2 and 4). ESMO Targeted Anticancer Therapies Congress 2025;Abstract 8O. Okamoto I et al. TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer. Future Oncol 2024;20(37):2927-36. Abstract Levy BP et al. TROPION-Lung08: Phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC. Future Oncol 2023;19(21):1461-72. Abstract Aggarwal C et al. AVANZAR: Phase III study of datopotamab deruxtecan (Dato-DXd) + durvalumab + carboplatin as 1L treatment of advanced/mNSCLC. World Conference on Lung Cancer (WCLC) 2023;Abstract P2.04-02. TROP2-Targeting Antibody-Drug Conjugates as Neoadjuvant and/or Adjuvant Therapy for Patients with Resectable NSCLC (19:08) A phase III, randomised, open-label, global study of adjuvant datopotamab deruxtecan (Dato-DXd) in combination with rilvegostomig or rilvegostomig monotherapy versus standard of care, following complete tumour resection, in participants with Stage I adenocarcinoma non-small cell lung cancer who are ctDNA-positive or have high-risk pathological features (TROPION-Lung12). NCT06564844 Cascone T et al. Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: The platform phase 2 NeoCOAST-2 trial. Nat Med 2025;31(8):2788-96. Abstract CME information and select publications

The leaves are turning, decorative gourds are everywhere, and the law school admissions cycle is in full swing. We break it all down, from the statistics regarding enrolling 1L classes (up), to LSAT numbers (up!), to a look ahead at what this likely means for application numbers (UP!).Also see if you can spot the error regarding the year in which Cecil Fielder hit over 50 home runs for the Detroit Tigers!If you'd like help with any aspect of your law school applications, check out all of our services here.

Will is a George Washington Law School Graduate and currently works as an Assistant Attorney General at the Fraud and Corruption Unit at the Maryland Office of the Attorney General. Will's journey exemplifies the unique journey, with 11 years in between his graduation from undergraduate, to finally arriving at Law School. Will and I started years before George Washington Law School, speaking on getting that real-world experience in different industries, before Law School. Will wanted to go to Law School and had family who were lawyers, but felt the expense was not quite worth it. Will would do work in water systems for some years, and then decide to head down to Austin for his most ambitious venture, opening up a food truck. Will spoke about his 2-year food truck experience and the chaos that ensued daily. Will notes the hard times of running a food truck, making Law School all the more easier. Will then spoke on his 1L year at the George Washington Law School, which he enjoyed thoroughly, and then Covid hit and fundamentally changed his Law School experience.Will talked about the various internships and clerkships he had, and what he learned from them, leading to today, where he works as an Assistant Attorney General. Finally, Will and I talked about his book, Law School Essentials: A Grad's Guide to What Matters Most. We would speak about doing what you're good at, having a direction and being specific, having detachment from bad grades, and embracing failure to continue to improve. This episode will further show that no matter the age, and no matter the timing, your Law School journey is solely defined by you and your goals! Be sure to check out Will's Book, Law School Essentials: A Grad's Guide to What Matters Most, below!Will's LinkedIn: https://www.linkedin.com/in/williamelmanLaw School Essentials: A Grad's Guide to What Matters Most: https://a.co/d/b9VVgLfBe sure to check out the Official Sponsors for the Lawyers in the Making Podcast:Rhetoric - takes user briefs and motions and compares them against the text of opinions written by judges to identify ways to tailor their arguments to better persuade the judges handling their cases. Rhetoric's focus is on persuasion and helps users find new ways to improve their odds of success through more persuasive arguments. Find them here: userhetoric.comThe Law School Operating System™ Recorded Course - This course is for ambitious law students who want a proven, simple system to learn every topic in their classes to excel in class and on exams. Go to www.lisablasser.com, check out the student tab with course offerings, and use code LSOSNATE10 at checkout for 10% off Lisa's recorded course!Start LSAT - Founded by former guest and 22-year-old superstar, Alden Spratt, Start LSAT was built upon breaking down barriers, allowing anyone access to high-quality LSAT Prep. For $110, you get yourself the Start LSAT self-paced course, and using code LITM10 you get 10% off the self-paced course! Check out Alden and Start LSAT at startlsat.com and use code LITM10 for 10% off the self-paced course!Lawyers in the Making Podcast is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Get full access to Lawyers in the Making Podcast at lawyersinthemaking.substack.com/subscribe

Mishna Yomi - Menachos 11:9-12:1L'uli Nishmas Etta Ahuva bas YaakovOct 13, 2025Mon21 Tishrei 5786

Mishna Yomi - Menachos 9:9-10:1L'uli Nishmas Etta Ahuva bas YaakovOct 4, 2025Shab12 Tishrei 5786

Featuring an interview with Dr Kevin Kalinsky, including the following topics: Patient-Reported Outcomes from the TROPION-Breast01 Study (0:00) Pernas S et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Patient-reported outcomes from the TROPION-Breast01 study. ASCO 2024;Abstract 1006. Indirect Comparison of Sacituzumab Govitecan and Datopotamab Deruxtecan for Advanced Breast Cancer (5:04) Pathak N et al. Indirect comparison of sacituzumab govitecan (SG) and datopotamab deruxtecan (Dato-DXd) in advanced breast cancer (aBC): Safety and efficacy analysis. San Antonio Breast Cancer Symposium 2024;Abstract P1-02-02. BEGONIA: A Phase Ib/II Study of Datopotamab Deruxtecan with Durvalumab as First-Line Treatment for Unresectable Advanced Triple-Negative Breast Cancer (9:53) Schmid P et al. Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study. ESMO 2023;Abstract 379MO. Advances in the Use of TROP2-Targeted Antibody-Drug Conjugates for Breast Cancer: Mechanisms, Clinical Applications and Future Directions (15:35) Tong Y et al. Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: Mechanisms, clinical applications, and future directions. Front Immunol 2024;15:1495675. Abstract CME information and select publications

Mishna Yomi - Menachos 7:6-8:1L'uli Nishmas Etta Ahuva bas YaakovSep 26, 2025Fri4 Tishrei 5786

Mishna Yomi - Menachos 6:7-7:1L'uli Nishmas Etta Ahuva bas YaakovSep 23, 2025Tue1 Tishrei 5786

In this special episode of Legally Bond, we get a chance to hear from Bond's newest class of associate trainees. Tim Bouffard, Cecilia Brey, Alex Brockhuizen, MacKenzie DiLeo, Grant Haffenden, McKenzie Kestler, Lindsay McCarthy, David Reinharz, Courtney Ryan, Lexi Takashima, Sheila Tapia, Joseph Vogt and Diana Waligora share what advice they'd impart on their 1L selves, why they are excited to be a part of the Bond team and more.

Featuring an interview with Dr Jacob Sands, including the following topics: Management of Adverse Events of Special Interest Associated with Datopotamab Deruxtecan (Dato-DXd) (0:00) Heist RS et al. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev 2024;125:102720. Abstract  Sands J et al. Analysis of drug-related interstitial lung disease (ILD) in patients (pts) treated with datopotamab deruxtecan (Dato-DXd). ASCO 2024;Abstract 8623. Intracranial Efficacy of Dato-DXd for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Actionable Genomic Alterations in the TROPION-Lung05 Study (7:23) Lisberg A et al. Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05. ASCO 2024;Abstract 8593.  Clinical Evidence Supporting the Combination of Dato-DXd with Immune Checkpoint Inhibition for Advanced NSCLC (12:12) Bessede A et al. TROP2 is associated with primary resistance to immune checkpoint inhibition in patients with advanced non-small cell lung cancer. Clin Cancer Res 2024;30(4):779-85. Abstract Levy BP et al. TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC). ASCO 2025;Abstract 8501. Waqar SN et al. First-line (1L) datopotamab deruxtecan (Dato-DXd) + rilvegostomig in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohort 5). ASCO 2025;Abstract 8521. Current and Future Development of Antibody-Drug Conjugates in the Treatment of Lung Cancer (17:11) Tawfiq RK et al. Targeting lung cancer with precision: The ADC therapeutic revolution. Curr Oncol Rep 2025;27(6):669-86. Abstract CME information and select publications

#300th for 4th of September, 2025 or 3311! (33-Oh-Leven, not Oh-Eleven, OH-Leven)http://loosescrewsed.comJoin us on discord! And check out the merch store! PROMO CODEShttps://discord.gg/3Vfap47ReaSupport us on Patreon: https://www.patreon.com/LooseScrewsEDSquad Update:  (Updated by Bloom 8/14)It's been one week since anyone said on this weekly podcast that the BGS is broken. Operation Highway to Hell is the new Operation Keg Stand! - Powerplay channel for detailsExpansion out of V640C complete - Welcome to G 172-15!Undermine Hudson Meat Puppet in Alexandrinus! PowerPlay Update: - Cycle 45We lost the battle in Alexandrinus but the war is not overMore in PowerPlay HubKruger 5's Power Rankings - https://k5elite.com/ Niceygy's Power Points - https://elite.niceygy.net/powerpointsFind out more in the LSN-powerplay-hub forum channel.Galnet Update: https://community.elitedangerous.com/Dev News: Type 11 Video Deep DiveEngines pulls in for landing, and when cargo hatch is open (for tight maneuvering)8 hard points4 reserved for mining gear 1L, 2M, 1S1M, 3SNew Large Mining laser - gatling gun/energy projectile: laser mining and abrasion12 Internals, 2 restricted2x1, 1x2, 1x3, 1x4, 4x5, 3x62 restricted Size-5s: 1 for SLF, 1 for drone controllers and New Size-5 “Mining Drone Controller” - only for Type11Core InternalsPower Plant - 6Thrusters - 5FSD - 5Life Support - 3Distro - 7Sensors - 3Fuel Tank - 5Release September 23Discussion:300th EpisodeScrews Across the Galaxy - Show StatsChig Or Fiction1. “It's god awful.  It's worth the price of admission.”2. “I gotta take a piss.  Keep talking.” (Tracks, Lark, Oblivious, Chig)3. “We could just do a whole show about octopus.” (Grover, Bloomingwind, Baromir, nlHate)Loose Threads - Screwy MemoriesLive Q&ACommunity Corner:Roy's Stories Season 2: Special Loose Screws 300th Episode is available now in the DS3 channel

Welcome back to the Law School Toolbox podcast! In this episode we offer practical advice for law students on preparing for class, handling the Socratic method, and managing anxiety about being called on. We emphasize that mistakes are normal and that efficient reading and note-taking are key. We encourage law students to approach class participation as a learning opportunity and to focus on developing confidence and communication skills. In this episode we discuss: What is the Socratic method and why do law schools use it? What is the most effective way to prepare for a law school class? How to manage anxiety about classroom participation What if you're genuinely unprepared for class one day? Resources Start Law School Right! (https://lawschooltoolbox.com/start-law-school-right/) Podcast Episode 62: Surviving the Socratic Method in Law School (https://lawschooltoolbox.com/podcast-episode-62-surviving-the-socratic-method-in-law-school-classes/) Podcast Episode 102: How to Read Cases and Prepare for Class in Law School (https://lawschooltoolbox.com/16176-2/) Podcast Episode 398: Start Law School Right – The Socratic Method (https://lawschooltoolbox.com/podcast-episode-398-start-law-school-right-the-socratic-method/) Be Prepared and Speak Up! A Different Approach to the Socratic Method (https://lawschooltoolbox.com/be-prepared-and-speak-up-a-different-approach-to-the-socratic-method/) What's the Point of Reading Cases in Law School? (https://lawschooltoolbox.com/whats-the-point-of-reading-cases-in-law-school/) Notes? Case Briefs? Highlighting? How Do You Prepare for Class? (https://lawschooltoolbox.com/notes-case-briefs-highlighting-how-do-you-prepare-for-class/) Ahead of the Curve: What Should You Be Doing to Prepare for Class as a 1L and How Long Should It Take? (https://lawschooltoolbox.com/ahead-of-the-curve-what-should-you-be-doing-to-prepare-for-class-as-a-1l-and-how-long-should-it-take/) Download the Transcript  (https://lawschooltoolbox.com/episode-515-how-to-prepare-for-class-and-not-freak-out-when-you-get-called-on-1l-summer-series/) If you enjoy the podcast, we'd love a nice review and/or rating on Apple Podcasts (https://itunes.apple.com/us/podcast/law-school-toolbox-podcast/id1027603976) or your favorite listening app. And feel free to reach out to us directly. You can always reach us via the contact form on the Law School Toolbox website (http://lawschooltoolbox.com/contact). If you're concerned about the bar exam, check out our sister site, the Bar Exam Toolbox (http://barexamtoolbox.com/). You can also sign up for our weekly podcast newsletter (https://lawschooltoolbox.com/get-law-school-podcast-updates/) to make sure you never miss an episode! Thanks for listening! Alison & Lee